Zylox-Tonbridge Medical Technology Co., Ltd. Class H

As of June 30, 2025, Zylox-Tonbridge Medical Technology Co., Ltd. Class H carries a market capitalization of 6.61B, placing it among publicly traded companies globally. Its enterprise value stands at 4.93B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Zylox-Tonbridge Medical Technology Co., Ltd. Class H's next confirmed earnings release is scheduled for March 25, 2027.

As of June 30, 2025, Zylox-Tonbridge Medical Technology Co., Ltd. Class H has 317.74M shares outstanding.

These figures are as of June 30, 2025.

As of June 30, 2025, Zylox-Tonbridge Medical Technology Co., Ltd. Class H maintains a current ratio of 5.77, meaning it holds 5.8x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2025.

As of the close on October 22, 2026, Zylox-Tonbridge Medical Technology Co., Ltd. Class H's stock has declined approximately 18.43% over the past 52 weeks. The 50-day moving average sits at 20.85, while the 200-day moving average is 21.58.

As of June 30, 2025, Zylox-Tonbridge Medical Technology Co., Ltd. Class H holds 1.77B in cash and equivalents against 91.08M in total debt, resulting in a net debt position of -423.07M. Total book value stands at 3.46B, with working capital of 1.69B providing operational flexibility.